Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tarceva Price Will Be In Bounds, OSI Says: Above Iressa, Below Gleevec

Executive Summary

Genentech/OSI will price the EGFR inhibitor Tarceva between AstraZeneca's Iressa and Novartis' Gleevec, OSI CEO Colin Goddard, PhD, said

You may also be interested in...



OSI Tarceva Approval Falls Flat: Wall Street Wants Aggressive Pricing

OSI's early experience with the launch of Tarceva suggests that managing investor expectations for a new-model breakthrough medicine may be as challenging as demonstrating a survival benefit in lung cancer

OSI Tarceva Approval Falls Flat: Wall Street Wants Aggressive Pricing

OSI's early experience with the launch of Tarceva suggests that managing investor expectations for a new-model breakthrough medicine may be as challenging as demonstrating a survival benefit in lung cancer

Cancer Drugs Will Continue To Command High Prices, Scully Predicts

The transformation in the Medicare market will not prevent cancer drugs from commanding very high prices, former Centers for Medicare & Medicaid Services Administrator Tom Scully predicted during the Washington Research Group's annual symposium Nov. 5

Related Content

Topics

UsernamePublicRestriction

Register

PS044521

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel